WO2005095409A3 - Tetrahydroquinoline derivatives and a process for preparing the same - Google Patents

Tetrahydroquinoline derivatives and a process for preparing the same Download PDF

Info

Publication number
WO2005095409A3
WO2005095409A3 PCT/JP2005/006894 JP2005006894W WO2005095409A3 WO 2005095409 A3 WO2005095409 A3 WO 2005095409A3 JP 2005006894 W JP2005006894 W JP 2005006894W WO 2005095409 A3 WO2005095409 A3 WO 2005095409A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparing
same
alkyl
optionally substituted
tetrahydroquinoline derivatives
Prior art date
Application number
PCT/JP2005/006894
Other languages
French (fr)
Other versions
WO2005095409A2 (en
Inventor
Hitoshi Kubota
Masakatsu Sugahara
Mariko Furukawa
Mayumi Takano
Daisuke Motomura
Original Assignee
Tanabe Seiyaku Co
Hitoshi Kubota
Masakatsu Sugahara
Mariko Furukawa
Mayumi Takano
Daisuke Motomura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200601852A priority Critical patent/EA011670B1/en
Priority to JP2006534487A priority patent/JP4565077B2/en
Application filed by Tanabe Seiyaku Co, Hitoshi Kubota, Masakatsu Sugahara, Mariko Furukawa, Mayumi Takano, Daisuke Motomura filed Critical Tanabe Seiyaku Co
Priority to AT05728670T priority patent/ATE556077T1/en
Priority to PL05728670T priority patent/PL1730152T3/en
Priority to BRPI0509364A priority patent/BRPI0509364B8/en
Priority to CA2560402A priority patent/CA2560402C/en
Priority to EP05728670A priority patent/EP1730152B1/en
Priority to DK05728670.0T priority patent/DK1730152T3/en
Priority to NZ550268A priority patent/NZ550268A/en
Priority to AU2005228290A priority patent/AU2005228290B2/en
Priority to ES05728670T priority patent/ES2383900T3/en
Priority to MXPA06011415A priority patent/MXPA06011415A/en
Publication of WO2005095409A2 publication Critical patent/WO2005095409A2/en
Publication of WO2005095409A3 publication Critical patent/WO2005095409A3/en
Priority to IL178195A priority patent/IL178195A/en
Priority to US11/527,691 priority patent/US7872126B2/en
Priority to NO20065011A priority patent/NO20065011L/en
Priority to US12/911,149 priority patent/US8158640B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

A novel compound of the formula (I): wherein R1 is alkoxycarbonyl or the like, R2 is alkyl or the like; R3 is hydrogen or the like; R4 is alkylene or the like; R5 is optionally substituted heterocyclic group; R6, R7, R8 and R9 are independently hydrogen; alkyl, alkoxy, or the like; R10 is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).
PCT/JP2005/006894 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same WO2005095409A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
NZ550268A NZ550268A (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same
DK05728670.0T DK1730152T3 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and process for their preparation
AT05728670T ATE556077T1 (en) 2004-04-02 2005-04-01 TETRAHYDROCHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
PL05728670T PL1730152T3 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same
BRPI0509364A BRPI0509364B8 (en) 2004-04-02 2005-04-01 tetrahydroquinoline derivatives, pharmaceutical composition comprising them and a process for preparing said derivatives
CA2560402A CA2560402C (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same
JP2006534487A JP4565077B2 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivative and process for producing the same
EA200601852A EA011670B1 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same
EP05728670A EP1730152B1 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same
ES05728670T ES2383900T3 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a procedure for their preparation
AU2005228290A AU2005228290B2 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same
MXPA06011415A MXPA06011415A (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same.
IL178195A IL178195A (en) 2004-04-02 2006-09-19 Tetrahydroquinoline derivatives and a process for preparing the same
US11/527,691 US7872126B2 (en) 2004-04-02 2006-09-27 Tetrahydroquinoline derivatives and a process for preparing the same
NO20065011A NO20065011L (en) 2004-04-02 2006-11-01 Tetrahydroquinoline derivatives and processes for their preparation
US12/911,149 US8158640B2 (en) 2004-04-02 2010-10-25 Tetrahydroquinoline derivatives and a process for preparing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-109550 2004-04-02
JP2004109550 2004-04-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/527,691 Continuation-In-Part US7872126B2 (en) 2004-04-02 2006-09-27 Tetrahydroquinoline derivatives and a process for preparing the same

Publications (2)

Publication Number Publication Date
WO2005095409A2 WO2005095409A2 (en) 2005-10-13
WO2005095409A3 true WO2005095409A3 (en) 2006-02-09

Family

ID=34963484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/006894 WO2005095409A2 (en) 2004-04-02 2005-04-01 Tetrahydroquinoline derivatives and a process for preparing the same

Country Status (25)

Country Link
US (2) US7872126B2 (en)
EP (1) EP1730152B1 (en)
JP (1) JP4565077B2 (en)
KR (1) KR100905684B1 (en)
CN (2) CN101381345A (en)
AR (2) AR048361A1 (en)
AT (1) ATE556077T1 (en)
AU (1) AU2005228290B2 (en)
BR (1) BRPI0509364B8 (en)
CA (1) CA2560402C (en)
DK (1) DK1730152T3 (en)
EA (1) EA011670B1 (en)
EC (1) ECSP066967A (en)
ES (1) ES2383900T3 (en)
IL (1) IL178195A (en)
MX (1) MXPA06011415A (en)
MY (1) MY158055A (en)
NO (1) NO20065011L (en)
NZ (1) NZ550268A (en)
PL (1) PL1730152T3 (en)
PT (1) PT1730152E (en)
TW (1) TWI338684B (en)
UA (1) UA90269C2 (en)
WO (1) WO2005095409A2 (en)
ZA (1) ZA200608117B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2570688A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DOP2005000123A (en) 2004-07-02 2011-07-15 Merck Sharp & Dohme CETP INHIBITORS
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
JP4531027B2 (en) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 Pharmaceutical composition
JP2009512715A (en) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト Combination of renin inhibitor and anti-dyslipidemic agent and / or anti-obesity agent
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
TW200808731A (en) * 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2007001873A1 (en) * 2006-06-27 2008-01-04 Takeda Pharmaceutical ((3s)) - 6 - ((¨2,6-dimethyl-4- (3- (methylsulfonyl) -propoxy) biphenyl-3-yl) methoxy-2,3-dihydro-1-benzofuran-3-yl acid ) acetic or salt thereof
US7582691B2 (en) * 2007-01-17 2009-09-01 Sabic Innovative Plastics Ip B.V. Poly(arylene ether) compositions and articles
JP4834699B2 (en) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 Pharmaceutical composition
DK2207775T3 (en) 2007-11-05 2012-06-18 Novartis Ag 4-Benzylamino-1-carboxyacylpiperidine derivatives as CETP inhibitors useful in the treatment of diseases such as hyperlipidemia or arteriosclerosis
AU2012202172B2 (en) * 2007-11-05 2013-08-29 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
ATE528289T1 (en) 2007-12-03 2011-10-15 Novartis Ag 1,2-DISUBSTITUTED 4-BENZYLAMINOPYRROLIDINE DERIVATIVES AS CETP INHIBITORS SUITABLE FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS
SG175925A1 (en) 2009-05-15 2011-12-29 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
ES2430088T3 (en) 2009-05-15 2013-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
AR076706A1 (en) 2009-05-28 2011-06-29 Novartis Ag AMINOBUTIRIC DERIVATIVES REPLACED AS NEPRILISINE INHIBITORS
JP5654608B2 (en) 2009-11-17 2015-01-14 ノバルティス アーゲー Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
ES2472446T3 (en) 2009-11-30 2014-07-01 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
CA2804924C (en) * 2010-07-09 2016-06-28 Daiichi Sankyo Company, Limited Substituted pyridine compound
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
CA2850022C (en) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
JP6097225B2 (en) * 2012-01-06 2017-03-15 第一三共株式会社 Acid addition salts of substituted pyridine compounds
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
MX367525B (en) 2013-02-14 2019-08-26 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors.
BR112016001376A2 (en) 2013-07-25 2017-10-24 Novartis Ag synthetic apelin polypeptide bioconjugates
EA201690278A1 (en) 2013-07-25 2016-06-30 Новартис Аг CYCLIC POLYPEPTIDES FOR TREATMENT OF HEART FAILURE
PT3102212T (en) 2014-02-05 2019-02-06 Dezima Pharma B V Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
HUE059947T2 (en) * 2014-08-12 2023-01-28 Newamsterdam Pharma B V Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
KR102454984B1 (en) * 2014-08-28 2022-10-17 뉴암스테르담 파마 비.브이. PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS
JP2018507187A (en) 2015-01-23 2018-03-15 ノバルティス アーゲー Synthetic apelin fatty acid conjugates with improved half-life
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
WO2017023166A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
JOP20190086A1 (en) 2016-10-21 2019-04-18 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
WO2022177428A1 (en) * 2021-02-18 2022-08-25 Newamsterdam Pharma B.V. Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia
EP4125911A1 (en) * 2021-03-05 2023-02-08 NewAmsterdam Pharma B.V. Obicetrapib for treatment of dementias
CN113499860A (en) * 2021-07-08 2021-10-15 江西新金叶实业有限公司 Efficient flotation method for smelting slag recycled by copper regeneration
AU2022320869A1 (en) 2021-07-26 2024-02-01 Newamsterdam Pharma B.V. Treatment of his hyporesponders
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2024009144A1 (en) 2022-07-05 2024-01-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038194A1 (en) * 1997-02-28 1998-09-03 Rhone-Poulenc Rorer S.A. Thiazolobenzoheterocycles, preparation and medicines containing same
FR2763590A1 (en) * 1997-05-22 1998-11-27 Synthelabo New ((((Aryl methyl)amino)carbonyl)alkyl)-aromatic acid derivatives with hypoglycaemic activity
WO2000017165A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000017166A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (en) * 1999-11-30 2001-06-13 Pfizer Prod Inc PROCEDURE FOR OBTAINING 1,2,3,4-TETRAHYDROQUINOLINS 4-CARBOXYAMIN-2-SUBSTITUTED.
JP2001348332A (en) * 2000-04-07 2001-12-18 Takeda Chem Ind Ltd Soluble beta-amyloid precursor protein secretion accelerator
JP2002053557A (en) * 2000-08-14 2002-02-19 Japan Tobacco Inc Apolipoprotein a-i-producing facilitator
CN100432070C (en) 2000-12-18 2008-11-12 埃科特莱茵药品有限公司 Novel sulfamides and their use as endothelin receptor antagonists
SE0101161D0 (en) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
US20030216398A1 (en) * 2001-04-05 2003-11-20 Mitsuru Kakihana Soluble beta amyloid precursor protein secretion promoters
RU2004123637A (en) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) PHARMACEUTICAL MEDICINAL FORMS OF CONTROLLED RELEASE OF THE CHOLESTEROL PROTEIN PROTEIN INHIBITOR
CA2570688A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JP4531027B2 (en) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 Pharmaceutical composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038194A1 (en) * 1997-02-28 1998-09-03 Rhone-Poulenc Rorer S.A. Thiazolobenzoheterocycles, preparation and medicines containing same
FR2763590A1 (en) * 1997-05-22 1998-11-27 Synthelabo New ((((Aryl methyl)amino)carbonyl)alkyl)-aromatic acid derivatives with hypoglycaemic activity
WO2000017165A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000017166A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. E. HICKS ET AL: "differential effect of the novel non-peptidic opioid 4-tyrosylamido-6-benzyl-1,2,3,4 tetrahydroquinoline (CGPM-9) on in vitro rat t lymphocyte and macrophage functions", LIFE SCIENCE, vol. 68, no. 24, 2001, pages 2685 - 2694, XP002354487 *
WANG C ET AL: "Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 19, 6 October 1998 (1998-10-06), pages 2685 - 2688, XP004139601, ISSN: 0960-894X *

Also Published As

Publication number Publication date
ZA200608117B (en) 2007-12-27
UA90269C2 (en) 2010-04-26
CA2560402C (en) 2011-09-13
MXPA06011415A (en) 2006-12-20
EP1730152B1 (en) 2012-05-02
TW200536829A (en) 2005-11-16
NZ550268A (en) 2009-08-28
KR20060135856A (en) 2006-12-29
BRPI0509364A (en) 2007-09-04
PL1730152T3 (en) 2012-09-28
KR100905684B1 (en) 2009-07-03
AU2005228290A1 (en) 2005-10-13
EA011670B1 (en) 2009-04-28
TWI338684B (en) 2011-03-11
CN100528878C (en) 2009-08-19
ES2383900T3 (en) 2012-06-27
US7872126B2 (en) 2011-01-18
BRPI0509364B1 (en) 2018-07-03
BRPI0509364B8 (en) 2021-05-25
AU2005228290B2 (en) 2008-07-17
NO20065011L (en) 2006-12-29
JP2007530443A (en) 2007-11-01
DK1730152T3 (en) 2012-07-30
IL178195A (en) 2016-05-31
ECSP066967A (en) 2007-01-26
US20070082896A1 (en) 2007-04-12
CA2560402A1 (en) 2005-10-13
IL178195A0 (en) 2006-12-31
PT1730152E (en) 2012-05-21
EP1730152A2 (en) 2006-12-13
US20110039828A1 (en) 2011-02-17
ATE556077T1 (en) 2012-05-15
AR048361A1 (en) 2006-04-19
CN1938314A (en) 2007-03-28
US8158640B2 (en) 2012-04-17
WO2005095409A2 (en) 2005-10-13
AR107377A2 (en) 2018-04-25
MY158055A (en) 2016-08-30
CN101381345A (en) 2009-03-11
EA200601852A1 (en) 2007-04-27
JP4565077B2 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
WO2005095409A3 (en) Tetrahydroquinoline derivatives and a process for preparing the same
MY139887A (en) Tetrahydronaphthyridine derivatives and a process for preparing the same.
JO2994B1 (en) Cholesterol Ester Transfer Protein ( CETP) Inhibitors
WO2007081570A3 (en) Cholesteryl ester transfer protein inhibitors
LU92824I2 (en) CERITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2007041494A3 (en) Cholesteryl ester transfer protein inhibitors
TW200800947A (en) Trisubstituted amine compound
WO2008111604A1 (en) Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same
HK1077567A1 (en) Dibenzylamine compound and medicinal use thereof
EP1527049B8 (en) Fused heterocyclic compounds as peptidase inhibitors
WO2008093674A1 (en) Novel thiadiazole derivative having kinase inhibitory activity
WO2008010048A3 (en) Novel 2-substituted methyl penam derivatives
TNSN06456A1 (en) Cetp inhibitors
EP1057819A4 (en) Phthalazine derivatives and remedies for erectile dysfunction
TW200510361A (en) Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives
WO2004046107A8 (en) Indole derivatives as somatostatin agonists or antagonists
WO2010082212A3 (en) N-biphenylacyl thiazolidine-2,4-dione derivatives, their synthesis and uses
DK1303514T3 (en) Process for the preparation of azacycloalkanoylaminothiazoles
EP1908752A4 (en) Novel 2-quinolone derivative
PL361850A1 (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
WO2006013049A3 (en) Benzyloxy derivatives as maob inhibitors
UA84603C2 (en) Tetrahydronaphthyridine derivatives and process for the preparation thereof
CA2377233A1 (en) Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof
GB0427491D0 (en) Process and compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2560402

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 178195

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11527691

Country of ref document: US

Ref document number: 12006501916

Country of ref document: PH

Ref document number: 2006534487

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005228290

Country of ref document: AU

Ref document number: 3616/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005728670

Country of ref document: EP

Ref document number: 2006/08117

Country of ref document: ZA

Ref document number: 550268

Country of ref document: NZ

Ref document number: 1020067020435

Country of ref document: KR

Ref document number: 200608117

Country of ref document: ZA

Ref document number: 200580010398.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011415

Country of ref document: MX

Ref document number: 1200601618

Country of ref document: VN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005228290

Country of ref document: AU

Date of ref document: 20050401

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005228290

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 06111125

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200601852

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005728670

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067020435

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11527691

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0509364

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2005228290

Country of ref document: AU

Date of ref document: 20050401

Kind code of ref document: B